J. Safra Sarasin Holding AG Purchases 1,741 Shares of Regeneron Pharmaceuticals, Inc. $REGN

J. Safra Sarasin Holding AG lifted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 309.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,303 shares of the biopharmaceutical company’s stock after acquiring an additional 1,741 shares during the quarter. J. Safra Sarasin Holding AG’s holdings in Regeneron Pharmaceuticals were worth $1,295,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Dodge & Cox boosted its stake in Regeneron Pharmaceuticals by 64.6% in the second quarter. Dodge & Cox now owns 3,826,283 shares of the biopharmaceutical company’s stock worth $2,008,799,000 after purchasing an additional 1,502,198 shares in the last quarter. Norges Bank bought a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at about $628,151,000. Acadian Asset Management LLC raised its holdings in shares of Regeneron Pharmaceuticals by 234.7% in the second quarter. Acadian Asset Management LLC now owns 465,740 shares of the biopharmaceutical company’s stock valued at $244,480,000 after buying an additional 326,583 shares during the last quarter. Loomis Sayles & Co. L P lifted its position in Regeneron Pharmaceuticals by 18.6% during the 2nd quarter. Loomis Sayles & Co. L P now owns 1,941,070 shares of the biopharmaceutical company’s stock worth $1,019,062,000 after buying an additional 305,089 shares in the last quarter. Finally, Invesco Ltd. grew its holdings in Regeneron Pharmaceuticals by 26.5% during the 2nd quarter. Invesco Ltd. now owns 1,075,824 shares of the biopharmaceutical company’s stock worth $564,808,000 after acquiring an additional 225,078 shares during the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Regeneron Pharmaceuticals

In related news, VP Jason Pitofsky sold 431 shares of the stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $651.43, for a total value of $280,766.33. Following the sale, the vice president directly owned 4,233 shares in the company, valued at $2,757,503.19. This trade represents a 9.24% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Bonnie L. Bassler sold 1,500 shares of the business’s stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the transaction, the director owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. This represents a 46.83% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 2.6%

NASDAQ:REGN opened at $751.13 on Thursday. The company has a quick ratio of 3.33, a current ratio of 4.06 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $821.11. The stock’s fifty day simple moving average is $758.43 and its 200-day simple moving average is $647.96. The firm has a market capitalization of $78.94 billion, a P/E ratio of 17.99, a P/E/G ratio of 2.01 and a beta of 0.39.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, beating the consensus estimate of $9.73 by $2.10. The firm had revenue of $3.75 billion for the quarter, compared to analyst estimates of $3.57 billion. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The company’s quarterly revenue was up .9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $12.46 earnings per share. Equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Wall Street Analyst Weigh In

REGN has been the subject of a number of research analyst reports. Wall Street Zen raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, January 10th. UBS Group boosted their price objective on shares of Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the stock a “neutral” rating in a research report on Friday, November 7th. Bank of America upgraded Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and increased their price objective for the company from $627.00 to $860.00 in a research report on Wednesday, January 7th. Truist Financial boosted their target price on Regeneron Pharmaceuticals from $798.00 to $820.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. Finally, Cantor Fitzgerald raised their price target on Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the company an “overweight” rating in a report on Wednesday, October 29th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $784.77.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.